Current ratio of Supernus Pharmaceuticals, Inc.
The current ratio is an indication of a company's liquidity and measures the capability to meet a company's short-term obligations. It compares a firm's current assets to its current liabilities, and is expressed as current assets divided by current liabilities. The ratio is only useful when two companies are compared within industry because inter industry business operations differ substantially. To determine liquidity, the current ratio is not as helpful as the quick ratio, because it includes all those assets that may not be easily liquidated, like prepaid expenses and inventory.
Acceptable current ratios vary from industry to industry. In many cases an investor would consider a high current ratio to be better than a low current ratio, because a high current ratio indicates that the company is more likely to pay the investor back. Large current ratios are not always a good sign for investors. If the company's current ratio is too high it may indicate that the company is not efficiently using its current assets or its short-term financing facilities. If current liabilities exceed current assets the current ratio will be less than 1. A current ratio of less than 1 indicates that the company may have problems meeting its short-term obligations.
Some types of businesses can operate with a current ratio of less than one however. If inventory turns into cash much more rapidly than the accounts payable become due, then the firm's current ratio can comfortably remain less than one. Inventory is valued at the cost of acquiring it and the firm intends to sell the inventory for more than this cost. The sale will therefore generate substantially more cash than the value of inventory on the balance sheet. Low current ratios can also be justified for businesses that can collect cash from customers long before they need to pay their suppliers.
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD. It also develops SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.
|Company||Industry||Return on equity|
|PX Praxair, Inc.||NYSE > Basic Industries > Major Chemicals||27.08%|
|MXIM Maxim Integrated Products, Inc.||NASDAQ > Technology > Semiconductors||27.17%|
|TPIC TPI Composites, Inc.||NASDAQ > Energy > Industrial Machinery/Components||27.18%|
|TSEM Tower Semiconductor Ltd.||NASDAQ > Technology > Semiconductors||27.19%|
|NMRK Newmark Group, Inc.||NASDAQ||27.19%|
|TEP Tallgrass Energy Partners, LP||NYSE > Public Utilities > Natural Gas Distribution||27.22%|
|SUPN Supernus Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||27.27%|
|OPNT Opiant Pharmaceuticals, Inc.||NASDAQ > Basic Industries > Precious Metals||2,031.11%|
|PBT Permian Basin Royalty Trust||NYSE > Energy > Oil & Gas Production||4,888.60%|
|IDXX IDEXX Laboratories, Inc.||NASDAQ > Health Care > Biotechnology: In Vitro & In Vivo Diagnostic Substances||8,410.92%|
|NRT North European Oil Royality Trust||NYSE > Energy > Oil & Gas Production||8,437.44%|
|CQH Cheniere Energy Partners LP Holdings, LLC||NYSEMKT > Public Utilities > Oil/Gas Transmission||9,523.81%|
|BPT BP Prudhoe Bay Royalty Trust||NYSE > Energy > Integrated oil Companies||9,929.09%|